Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid‑acting insulin analog presented as an injection solution for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring quality and regulatory compliance across all markets.

Insulin Aspart is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides rapid post‑prandial glucose control to achieve target glycaemic levels. - Type 2 diabetes mellitus (as adjunct therapy): helps reach glycaemic goals when combined with oral antidiabetic agents. - Gestational diabetes (when insulin therapy is required): offers fast‑acting glucose regulation during pregnancy.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed or dosing is excessive. - Injection site pain: mild discomfort or tenderness at the injection site. - Redness or swelling: localized erythema or oedema. - Lipodystrophy: changes in subcutaneous fat at repeated injection sites. - Allergic rash: mild skin eruption. - Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment requiring immediate assistance. - Anaphylactic reaction: life‑threatening allergic response with airway compromise. - Hypokalemia: low serum potassium, potentially precipitating cardiac arrhythmias. - Insulin antibody formation: may alter insulin efficacy. - Ketoacidosis despite therapy: rare metabolic decompensation. - Thrombotic events: extremely uncommon but reported in isolated cases.

Insulin Aspart requires careful monitoring and individualized dosing. - Dose adjustment: modify insulin dose when initiating or changing physical activity levels. - Blood glucose monitoring: check glucose frequently, especially during therapy initiation or dose changes. - Renal impairment: use with caution; reduced clearance may increase hypoglycaemia risk. - Hypersensitivity: discontinue if signs of allergic reaction such as rash, itching or swelling occur. - Do not mix: avoid mixing with other insulin formulations unless specifically instructed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin Aspart may interact with several concomitant medications.

Major Interactions (Avoid): - Sulfonylureas and meglitinides: additive hypoglycaemic effect. - High‑dose beta‑blockers: may mask hypoglycaemia symptoms. - Alcohol: can potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: may enhance insulin sensitivity. - Thiazide diuretics: can increase blood glucose levels. - Oral contraceptives: may affect insulin requirements. - Thyroid hormones: may alter glucose metabolism. - Corticosteroids: can raise glucose, requiring dose adjustments.